Nkarta, Inc. Announces \$100 Million At-the-Market Offering Program with Stifel

Nkarta, Inc. (Nasdaq: NKTX) has taken a significant step to bolster its financial flexibility by entering into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”) on March 25, 2026. This move enables Nkarta to offer and sell, at its sole discretion, up to \$100,000,000 worth of its common stock through an at-the-market (“ATM”) equity offering program.

Key Highlights and Details for Investors

• ATM Offering Structure: Under the Sales Agreement, Nkarta can issue and sell shares of its common stock, par value \$0.0001 per share, directly into the market or in negotiated transactions via Stifel acting as sales agent.
• Maximum Aggregate Offering Price: The total value of shares that may be sold under this program is capped at \$100 million, affording Nkarta substantial potential access to capital for general corporate purposes, R&D, or strategic initiatives.
• Sales Parameters: Nkarta retains full control over sales parameters, including:
  • The total number of shares to be issued
  • The time period during which sales may occur
  • Any minimum price thresholds
  • Limitations on the number of shares sold per trading day
• Sales Methods: The shares may be sold by any method that qualifies as an “at-the-market offering” under Rule 415(a)(4), including sales on the Nasdaq Global Select Market, other trading markets, over-the-counter, or privately negotiated transactions.
• Compensation to Stifel: The agent will receive a commission of up to 3% of gross sales proceeds for shares sold under the agreement. Nkarta also provides customary indemnification and contribution rights to Stifel.
• Termination Conditions: The Sales Agreement will terminate upon the earlier of (i) the sale of all shares under the program or (ii) a mutual termination in accordance with the agreement’s terms.
• Registration: All shares offered under this program are registered pursuant to Nkarta’s Form S-3 (File No. 333-294611), filed with the SEC on March 25, 2026, which includes an “at-the-market” prospectus supplement.
• Legal Opinion: O’Melveny & Myers LLP, acting as counsel to Nkarta, has issued a legal opinion affirming the validity of the shares to be issued and sold. The opinion is filed as Exhibit 5.1 to the Form 8-K.

Potential Shareholder Impact

• Share Dilution: The ATM program, if fully utilized, will result in the issuance of up to \$100 million in new common shares. While this capital raise can fund growth and strengthen the balance sheet, it will potentially dilute existing shareholders.
• Financial Flexibility: This program provides Nkarta with the means to raise capital expediently as needed, which can be critical for a clinical-stage biotech company navigating research, development, and commercialization milestones.
• Price Sensitivity: The announcement and subsequent share issuances under the ATM program may impact the market price of NKTX shares, depending on the scale and timing of sales, as well as investor perception of the company’s capital needs and use of proceeds.
• Regulatory Transparency: All relevant legal and regulatory documentation, including the Sales Agreement and legal opinion, are publicly available and incorporated by reference in Nkarta’s Form 8-K and Form S-3 filings for full investor transparency.

Conclusion

This announcement marks a pivotal development for Nkarta, Inc., providing the company with significant capital-raising flexibility. Investors should closely monitor subsequent disclosures regarding the use of proceeds and any material developments in Nkarta’s clinical or corporate strategy that may result from this financing capability.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should review the full SEC filings and consult with their financial advisors before making investment decisions. The author and publisher are not responsible for any actions taken based on this summary.

View Nkarta, Inc. Historical chart here